Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928186 · ClinicalTrials.gov registry record · NA
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
A NA study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01928186 is a NA study of Stage IIIA Breast Cancer and HER2/Neu Negative that has completed, run by University of Washington. The registered enrollment target is 28 participants, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01928186, a NA study of Stage IIIA Breast Cancer and HER2/Neu Negative, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I-III breast cancer. Comparing results of diagnostic procedures done before and during hormone therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG Fluorothymidine F-18
- DRUG Run-in (short pre-surgery course) of endocrine-targeted therapy
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-07-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928186
The ClinicalTrials.gov registry entry for NCT01928186 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT01928186 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01928186 about?
NCT01928186 is a clinical study titled "FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer". This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I-III breast cancer. Comparing results o...
What is the current status of trial NCT01928186?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2011-09. Estimated completion is 2015-07-20.
What conditions does trial NCT01928186 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, HER2/Neu Negative, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer.
What interventions are being tested in trial NCT01928186?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fluorothymidine F-18 (DRUG), Run-in (short pre-surgery course) of endocrine-targeted therapy (DRUG).
Who is sponsoring clinical trial NCT01928186?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01928186 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
-
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
COMPLETED · NA
-
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
COMPLETED · NA
-
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
COMPLETED · NA
-
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
COMPLETED · NA
-
Diindolylmethane in Treating Patients With Breast Cancer
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.